March 15, 2026 a 01:00 pm
ABT: Analysts Ratings - Abbott Laboratories
Abbott Laboratories, a leader in the healthcare sector, has consistently attracted significant attention from analysts. With well-diversified segments ranging from pharmaceuticals to medical devices, Abbott presents a balanced profile appealing to investors seeking both stability and growth opportunities. Recent analyst ratings indicate a predominantly positive sentiment towards the company's future performance.
Historical Stock Grades
As of March 2026, Abbott Laboratories has received a notable number of positive ratings from analysts. The majority classify the stock as 'Buy', demonstrating a strong confidence in its market position.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 6 | |
| Buy | 16 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 0 |
The historical ratings snapshot shows consistent positive sentiment from analysts.
The stock price chart provides an overview of Abbott's performance over the recent months.
Sentiment development
The sentiment regarding Abbott Laboratories has shown relative stability over the past year, primarily maintaining its Buy rating. The analyst evaluations have seen small fluctuations, with Buy ratings slightly increasing and Strong Buy ratings displaying minor reductions.
- The overall number of ratings has remained consistent month-to-month, suggesting sustained interest in the stock.
- Hold ratings saw a minor increase during early 2025, indicating cautious optimism or wait-and-see approaches by some analysts.
- The negligible Sell and Strong Sell ratings highlight continued confidence in Abbott's performance.
Percentage trends
Over the analyzed months, the distribution of ratings has shown intriguing shifts. While Strong Buy ratings have gradually diminished, implying a cautiously optimistic stance, Buy ratings have filled this gap, suggesting robust confidence in the stock's value.
- From early 2025 to early 2026, the percentage of Strong Buy ratings decreased from 40% to 20%.
- Buy ratings have seen a gradual increase, steadily holding above 50%.
- Hold ratings saw an uptick around mid-2025, reflecting possible short-term market unease.
This transition indicates a shift towards a more conservative yet still positive sentiment among analysts regarding Abbott Laboratories.
Latest Analyst Recommendations
Recent analyst actions for Abbott Laboratories indicate stable sustained positive sentiment. Most analysts chose to maintain their existing ratings, reflecting continued confidence in the company's strategy and market positioning.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-03-11 | Buy | Buy | Citigroup |
| 2026-02-02 | Overweight | Overweight | Barclays |
| 2026-01-23 | Outperform | Outperform | RBC Capital |
| 2026-01-23 | Buy | Buy | Citigroup |
| 2026-01-23 | Buy | Buy | BTIG |
Analyst Recommendations with Change of Opinion
While most ratings have been maintained, there have been occasions where opinions have shifted, reflecting dynamic market conditions. The noticeable upgrades were primarily from neutral or negative positions to more favorable ones, signaling renewed confidence in Abbott's prospects.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-18 | Buy | Hold | Jefferies |
| 2023-07-21 | Peer Perform | Underperform | Wolfe Research |
| 2023-07-20 | Peer Perform | Underperform | Wolfe Research |
| 2021-10-27 | Overweight | Neutral | Atlantic Equities |
| 2021-10-26 | Overweight | Neutral | Atlantic Equities |
Interpretation
The market perception of Abbott Laboratories' stock remains largely optimistic, characterized by the absence of Sell ratings and a steady stream of Buy and Strong Buy evaluations. Such a sentiment suggests a stable outlook, with analysts demonstrating confidence in the company's long-term strategies. Although there is evidence of cautious optimism through increased Hold ratings, the company's comprehensive portfolio across multiple healthcare segments continues to inspire confidence. This solid foundation positions Abbott well to withstand any potential market uncertainties.
Conclusion
In summary, Abbott Laboratories is perceived positively within the analyst community, reflecting a sound financial health and a strong market position. The lack of negativity in terms of Strong Sell or Sell ratings emphasizes an optimistic trajectory for the company. Analysts appear to appreciate the diversified revenue streams that Abbott provides, which offer a blend of growth and stability. As always, potential risks include market volatility and competitive pressures, yet the ongoing positive sentiment highlights Abbott's resilience and durability in the healthcare industry. Overall, Abbott Laboratories stands as an appealing investment, particularly for those seeking robust performance amidst a fluctuating market.